Tempus AI, Inc. Class A Common Stock (TEM) is a publicly traded Healthcare sector company. As of May 19, 2026, TEM trades at $44.70 with a market cap of $7.89B and a P/E ratio of -25.14. TEM moved +1.63% today. Year to date, TEM is -30.05%; over the trailing twelve months it is -33.39%. Its 52-week range spans $31.36 to $104.32. Analyst consensus is buy with an average price target of $65.19. Rallies surfaces TEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ventripoint Seeks China Approval for VMS+ 4.0, Showcases at AEPC Congress: Ventripoint submitted its VMS+ 4.0 echocardiography AI platform to China’s NMPA via an expedited green channel on April 28, targeting 330 million cardiovascular patients. The company also plans to showcase VMS+ at the AEPC congress in Padua (May 12–16) following new commercial agreements in California and First Nations communities.
| Metric | Value |
|---|---|
| Price | $44.70 |
| Market Cap | $7.89B |
| P/E Ratio | -25.14 |
| EPS | $-1.72 |
| Dividend Yield | 0.44% |
| 52-Week High | $104.32 |
| 52-Week Low | $31.36 |
| Volume | 3.20M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.36B |
| Net Income | $-302.91M |
| Gross Margin | 0.00% |
15 analysts cover TEM: 0 strong buy, 9 buy, 5 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $65.19.